microRNA 3609 (miR-3609)

microRNA 3609 (miR-3609) is a small, endogenous, non-coding RNA molecule that regulates gene expression at the post-transcriptional level by binding to complementary sequences in target mRNAs, resulting in mRNA degradation or translational repression. It is implicated in various cancer types, with abnormal expression linked to pancreatic cancer, glioma, polycystic ovary syndrome, and notably breast cancer—including triple-negative breast cancer, where higher miR-3609 levels are associated with a better prognosis. Functional studies demonstrate that miR-3609 inhibits cancer cell proliferation, induces cell cycle arrest (G0/G1), and may sensitize tumor cells to chemotherapy by suppressing immune checkpoint proteins such as PD-L1. MIcroRNA 3609 is emerging as both a prognostic biomarker and a potential therapeutic target in cancers where its dysregulation is observed.

Other names

hsa-mir-3609mir-3609hsa-miR-3609MIR3609

Post-transcriptional silencing of target mRNA by sequence-specific binding. Suppression of programmed death-ligand 1 (PD-L1) expression, leading to increased sensitivity of cancer cells to chemotherapy. Downregulation of cyclin-dependent kinase 1 (CDK1).